How many drugs treat Breakthrough cancer pain?

Drug Landscape tracks 2 marketed treatments for Breakthrough cancer pain (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/breakthrough-cancer-pain.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Breakthrough cancer pain — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Breakthrough cancer pain (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Breakthrough cancer pain, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Duragesic	fentanyl	Johnson & Johnson (Janssen Pharmaceutica)	Synthetic opioid analgesic	D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor		1968-01-01
Fentanyl (F2)	Fentanyl (F2)	Oslo University Hospital	Synthetic opioid	D(4) dopamine receptor, Solute carrier family 22 member 1, D(2) dopamine receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Johnson & Johnson (Janssen Pharmaceutica) · 1 drug in Breakthrough cancer pain
Oslo University Hospital · 1 drug in Breakthrough cancer pain

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Breakthrough cancer pain:

Cite this brief

Drug Landscape (2026). Breakthrough cancer pain — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/breakthrough-cancer-pain. Accessed 2026-06-10.

Breakthrough cancer pain full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing